Sinusitis, Acute, Medical Treatment Clinical Presentation
- Author: Steven E Sobol, MD, FRCSC, MSc, FAAP; Chief Editor: Arlen D Meyers, MD, MBA more...
History
Acute sinusitis is a clinical diagnosis; thus, an understanding of its presentation is of paramount importance in differentiating this entity from allergic or vasomotor rhinitis and common URTIs. No specific clinical symptom or sign is sensitive or specific for acute sinusitis, so the overall clinical impression should be used to guide management.
A consensus statement published in Otolaryngology-Head and Neck Surgery made strong recommendations that clinicians should distinguish between acute rhinosinusitis caused by bacterial causes and those episodes caused viral upper respiratory infections and noninfectious conditions.[3] The panel suggests that the diagnosis of acute bacterial sinusitis be entertained when (a) symptoms or signs of acute rhinosinusitis are present 10 days or more beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement. A history of purulent secretions and facial or dental pain are specific symptoms that may point to a bacterial etiology. In a patient in intensive care, acute sinusitis should be suspected in the presence of sepsis of unknown origin.
Physical
Anterior rhinoscopic examination, with or without a topical decongestant, is important to assess the status of the nasal mucosa and the presence and color of nasal discharge. Predisposing anatomical variations can also be noted during anterior rhinoscopy. Sinus transillumination and palpation are of little predictive value. A basic evaluation of ocular and neurological function is also necessary in order to rule out potential complications.
Endoscopic examination may reveal the origin of the purulent discharge from the middle meatus and may provide information about the nature of ostiomeatal obstruction. The use of endoscopy may also aid in the etiologic diagnosis of acute sinusitis by allowing the careful attainment of purulent secretions from the sinus ostia for culture.
Causes
The bacteria most commonly involved in acute sinusitis are part of the normal nasal flora. These bacteria can become sinus pathogens when they are deposited into the sinuses by sneezing, coughing, or direct invasion under conditions that optimize their growth. The most common bacterial pathogens in acute sinusitis are Streptococcus pneumoniae (30-40%), Haemophilus influenzae (20-30%), and Moraxella catarrhalis (12-20%). Staphylococcus aureus and Streptococcus pyogenes are isolated in rare cases. Sixty-six percent of patients with acute sinusitis grow at least 1 pathogenic bacterial species on sinus aspirates, while 26-30% percent of patients have multiple predominant bacterial species.
Anaerobic organisms have been found in fewer than 10% of patients with acute bacterial sinusitis, despite the ample environment available for their growth. The exceptions are in sinusitis resulting from a dental source and in patients with chronic sinus disease, in whom anaerobic organisms are usually isolated.
Gram-negative organisms, including Pseudomonas aeruginosa (15.9%), Escherichia coli (7.6%), Proteus mirabilis (7.2%), Klebsiella pneumoniae, and Enterobacter species, predominate in nosocomial sinusitis, accounting for 60% of cases. Polymicrobial invasion is seen in 25-100% of cultures. The other pathogenic organisms found in nosocomial patients are gram-positive organisms (31%) and fungi (8.5%). Viruses are the most common trigger of acute sinusitis. Rhinovirus, influenza, and parainfluenza viruses are the primary pathogens in 3-15% of patients with acute sinusitis.
Fungal causes of sinusitis are discussed in Allergic Fungal Sinusitis and Sinusitis, Fungal.
Bishai WR. Issues in the management of bacterial sinusitis. Otolaryngol Head Neck Surg. Dec 2002;127(6 Suppl):S3-9. [Medline].
Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol. Mar 1999;103(3 Pt 1):408-14. [Medline].
[Guideline] Rosenfeld RM, Andes D, Bhattacharyya N, Cheung D, Eisenberg S, Ganiats TG, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg. Sep 2007;137(3 Suppl):S1-31. [Medline].
Savolainen S, Jousimies-Somer H, Karjalainen J. Do simple laboratory tests help in etiologic diagnosis in acute maxillary sinusitis?. Acta Otolaryngol Suppl. 1997;529:144-7. [Medline].
Slack CL, Dahn KA, Abzug MJ, Chan KH. Antibiotic-resistant bacteria in pediatric chronic sinusitis. Pediatr Infect Dis J. Mar 2001;20(3):247-50. [Medline].
Sobol SE, Marchand J, Tewfik TL, Manoukian JJ, Schloss MD. Orbital complications of sinusitis in children. J Otolaryngol. Jun 2002;31(3):131-6. [Medline].
Chandler JR, Langenbrunner DJ, Stevens ER. The pathogenesis of orbital complications in acute sinusitis. Laryngoscope. Sep 1970;80(9):1414-28. [Medline].
[Guideline] Slavin RG, Spector SL, Bernstein IL, Kaliner MA, Kennedy DW, Virant FS, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol. Dec 2005;116(6 Suppl):S13-47. [Medline].
AHCPR Evidence Report. Agency for Health Care Policy and Research. In: Diagnosis and treatment of acute bacterial rhinosinusitis. Rockville, MD. 1999.
Brook I, Gooch WM III, Jenkins SG. Medical Management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. Ann Otol Rhinol Laryngol. 2000;109(Suppl):2-20.
Conrad DA, Jenson HB. Management of acute bacterial rhinosinusitis. Curr Opin Pediatr. 2002;14(1):86-90.
Eibling DE. Maxillary Sinus: Irrigation Techniques. In: Myers EN, ed. Operative Otolaryngology-Head and Neck Surgery. Philadelphia, Pa: WB Saunders; 1997:81-85.
Frenkiel S. Embryology of the Nose and Sinuses. In: Tewfik TL, Der Kaloustian VM, eds. Congenital Anomalies of the Ear, Nose, and Throat. New York: Oxford University Press; 1997:183-187.
Graney DO, Rice DH. Anatomy. In: Cummings CW, Frederickson JM, Harker LA, Krause CJ, Richardson MA, Schuller DE, eds. Otolaryngology-Head & Neck Surgery. 3rd ed. St. Louis: Mosby; 1998:1059-1064.
International Rhinosinusitis Advisory Board. Infectious rhinosinusitis in adults: classification, etiology and management. International Rhinosinusitis Advisory Board. Ear Nose Throat J. Dec 1997;76(12 Suppl):1-22. [Medline].
Johnson JT, Ferguson BJ. Infection. In: Cummings CW, Frederickson JM, Harker LA, Krause CJ, Richardson MA, Schuller DE, eds. Otolaryngology-Head & Neck Surgery. 3rd ed. St. Louis: Mosby; 1998:1107-1118.
Josephson GD, Gross CW. Diagnosis & management of acute & chronic sinusitis. Compr Ther. Nov 1997;23(11):708-14. [Medline].
Kaliner MA, Osguthorpe JD, Fireman P. Sinusitis: bench to bedside. Current findings, future directions. Otolaryngol Head Neck Surg. Jun 1997;116(6 Pt 2):S1-20. [Medline].
Laine K, Maatta T, Varonen H. Diagnosing acute maxillary sinusitis in primary care: a comparison of ultrasound, clinical examination and radiography. Rhinology. Mar 1998;36(1):2-6. [Medline].
Low DE, Desrosiers M, McSherry J. A practical guide for the diagnosis and treatment of acute sinusitis. CMAJ. Mar 15 1997;156 Suppl 6:S1-14. [Medline].
Manning SC. Medical Management of Infectious and Inflammatory Disease. In: Cummings CW, Frederickson JM, Harker LA, Krause CJ, Richardson MA, Schuller DE, eds. Otolaryngology-Head & Neck Surgery. 3rd ed. St. Louis: Mosby; 1998:1135-1144.
McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. Jan 18 1995;273(3):214-9. [Medline].
Poole MD. A focus on acute sinusitis in adults: changes in disease management. Am J Med. May 3 1999;106(5A):38S-47S; discussion 48S-52S. [Medline].
Rhys-Evans PH. Anatomy of the Nose and Paranasal Sinuses. In: Kerr AG, Groves J, eds. Scott-Brown's Otolaryngology. 5th ed. London: Butterworths; 1987:138-161.
Talmor M, Li P, Barie PS. Acute paranasal sinusitis in critically ill patients: guidelines for prevention, diagnosis, and treatment. Clin Infect Dis. Dec 1997;25(6):1441-6. [Medline].
Taylor JA, Weber W, Standish L, et al. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA. Dec 3 2003;290(21):2824-30. [Medline].
Wald ER. Expanded role of group A streptococci in children with upper respiratory infections. Pediatr Infect Dis J. Aug 1999;18(8):663-5. [Medline].
Wald ER. Microbiology of acute and chronic sinusitis in children and adults. Am J Med Sci. Jul 1998;316(1):13-20. [Medline].
Wald ER. Sinusitis. Pediatr Ann. Dec 1998;27(12):811-8. [Medline].
Westergren V. Artificial ventilation-acquired sinopathy in the critically ill - the maxillary sinuses revisited. Clin Exp Allergy. Mar 1999;29(3):298-305. [Medline].
| Antibiotic | Dosage | Streptococcus pneumoniae | Haemophilus influenzae | Moraxella catarrhalis | Anaerobic bacteria | ||
| Sensitive | Intermediate | Resistant | |||||
| Amoxicillin | 500 mg PO tid | +++ | ++ | + | ++ | + | + |
| Clarithromycin | 250-500 mg PO bid | ++ | ++ | + | ++ | +++ | + |
| Azithromycin | 500 mg PO first day, then 250 mg/d PO for 4 days | ++ | ++ | + | ++ | +++ | + |
| Antibiotic | Dosage | Streptococcus pneumoniae | Haemophilus influenzae | Moraxella catarrhalis | Anaerobic bacteria | ||
| Sensitive | Intermediate | Resistant | |||||
| Amoxicillin/clavulanate | 500 mg PO tid | +++ | ++ | + | +++ | +++ | +++ |
| Cefuroxime | 250-500 mg PO bid | +++ | ++ | + | +++ | ++ | ++ |
| Cefpodoxime + cefixime | 200 mg PO bid 400 mg/d PO | - ++ | +++ - | ++ - | + +++ | +++ +++ | +++ - |
| Ciprofloxacin | 500-750 mg PO bid | ++ | + | + | ++ | +++ | + |
| Levofloxacin | 500 mg/d PO | +++ | +++ | +++ | +++ | +++ | +++ |
| Trovafloxacin | 200 mg/d PO | +++ | +++ | +++ | +++ | +++ | +++ |
| Clindamycin | 300 mg PO tid | +++ | +++ | +++ | - | - | +++ |
| Metronidazole | 500 mg PO tid | - | - | - | - | - | +++ |
| Antibiotic | Dosage | Streptococcus pneumoniae | Haemophilus influenzae | Moraxella catarrhalis | Gram-negative | Anaerobic bacteria |
| Piperacillin | 3-4 g IV q4-6h | +++ | + | - | +++ | +++ |
| Piperacillin/tazobactam | 3.375 g IV q6h | +++ | +++ | +++ | +++ | ++ |
| Ticarcillin | 3 g IV q4h | +++ | - | - | +++ | ++ |
| Ticarcillin/clavulanate | 3.1 g IV q4h | +++ | +++ | - | +++ | ++ |
| Imipenem | 500 mg IV q6h | +++ | +++ | +++ | +++ | +++ |
| Meropenem | 1 g IV q8h | +++ | +++ | +++ | +++ | ++ |
| Cefuroxime | 1 g IV q8h | +++ | +++ | +++ | ++ | ++ |
| Ceftriaxone | 2 g IV bid | +++ | +++ | +++ | +++ | ++ |
| Cefotaxime | 2 g IV q4-6h | +++ | +++ | +++ | +++ | ++ |
| Ceftazidime | 2 g IV q8h | +++ | +++ | +++ | +++ | ++ |
| Gentamicin | 1.7 mg/kg IV q8h | - | +++ | +++ | ++ | - |
| Tobramycin | 1.7 mg/kg IV q8h | - | +++ | +++ | ++ | - |
| Vancomycin | 1 g IV q6-12h | +++ | - | - | - | ++ |

